CD Antigen Cancer Therapy Market Size, Share & Trends Analysis Report By Type of CD Antigen Targeted (CD19, CD20, CD30, CD33, CD38, CD70), By Therapy Type [Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins], By Cancer Type, By End User, By Region, And By Segment Forecasts, 2024-2031

Report Id: 2644 Pages: 170 Last Updated: 06 August 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of CD Antigen Cancer Therapy Market-

By Type of CD Antigen Targeted-

  • CD19
  • CD20
  • CD30
  • CD33
  • CD38
  • CD70
  • Others

ad antigen market

By Therapy Type-

  • Monoclonal Antibodies (mAbs)
  • Antibody-Drug Conjugates (ADCs)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy
  • Bi-specific T-cell Engagers (BiTEs)
  • Radioimmunotherapy
  • Immunotoxins

By Cancer Type-

  • Leukaemia
  • Lymphoma
  • Multiple Myeloma
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Others

By End-User-

  • Hospitals
  • Specialty Clinics
  • Cancer Treatment Centers
  • Research Institutes

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global CD Antigen Cancer Therapy Market Snapshot

Chapter 4. Global CD Antigen Cancer Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

5.1. By Type of CD Antigen Targeted & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type of CD Antigen Targeted:

5.2.1. CD19
5.2.2. CD20
5.2.3. CD30
5.2.4. CD33
5.2.5. CD38
5.2.6. CD70
5.2.7. Others

Chapter 6. Market Segmentation 2: By Therapy Type Estimates & Trend Analysis
6.1. By Therapy Type & Market Share, 2023 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapy Type:

6.2.1. Monoclonal Antibodies (mAbs)
6.2.2. Antibody-Drug Conjugates (ADCs)
6.2.3. Chimeric Antigen Receptor (CAR) T-cell Therapy
6.2.4. Bi-specific T-cell Engagers (BiTEs)
6.2.5. Radioimmunotherapy
6.2.6. Immunotoxins

Chapter 7. Market Segmentation 3: By Cancer Type Estimates & Trend Analysis
7.1. By Cancer Type & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Cancer Type:

7.2.1. Leukemia
7.2.2. Lymphoma
7.2.3. Multiple Myeloma
7.2.4. Breast Cancer
7.2.5. Lung Cancer
7.2.6. Prostate Cancer
7.2.7. Others

Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End User:

8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Cancer Treatment Centers
8.2.4. Research Institutes

Chapter 9. CD Antigen Cancer Therapy Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America
9.1.1. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.1.2. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.1.3. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.1.4. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.1.5. North America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

9.2. Europe
9.2.1. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.2.2. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.2.3. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.2.4. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.2.5. Europe CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

9.3. Asia Pacific
9.3.1. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.3.2. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.3.3. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.3.4. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.3.5. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

9.4. Latin America
9.4.1. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.4.2. Asia Pacific CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.4.3. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.4.4. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.4.5. Latin America CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

9.5. Middle East & Africa
9.5.1. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type of CD Antigen Targeted, 2024-2031
9.5.2. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
9.5.3. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Therapy Type, 2024-2031
9.5.4. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Cancer Type, 2024-2031
9.5.5. Middle East & Africa CD Antigen Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles

10.2.1. Novartis AG
10.2.2. Roche Holdings AG
10.2.3. Bristol Myers Squibb Company
10.2.4. Gilead Sciences Inc.
10.2.5. Merck & Co. Inc.
10.2.6. Johnson & Johnson
10.2.7. Amgen Inc.
10.2.8. AbbVie Inc.
10.2.9. AstraZeneca PLC
10.2.10. Takeda Pharmaceutical Company Limited
10.2.11. Seattle Genetics Inc.
10.2.12. Biogen Inc.
10.2.13. Celgene Corporation
10.2.14. Genmab A/S
10.2.15. Immunomedics Inc.
10.2.16. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5537
Security Code field cannot be blank!

Frequently Asked Questions

The CD Antigen Cancer Therapy Market Size is valued at USD 26.2 Bn in 2023 and is predicted to reach USD 41.8 Bn by 2031

The CD Antigen Cancer Therapy Market is expected to grow at a 6.21% CAGR during the forecast period for 2024-2031.

Novartis AG, Roche Holdings AG, Bristol Myers Squibb Company, Gilead Sciences Inc., Merck & Co. Inc., Johnson & Johnson, Amgen Inc., AbbVie Inc., Astr

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying